Drg Stimulator denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for drg stimulator are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied a Dorsal Root Ganglion Stimulator as Not FDA-Approved

This denial type — "not FDA-approved" — for a DRG stimulator is often factually incorrect or based on a mismatch between the specific indication documented in the claim and the FDA-approved indications for the device. DRG stimulation systems have received FDA Premarket Approval (PMA) for specific chronic pain indications. A denial citing lack of FDA approval may reflect: (a) a coding error in the claim; (b) use of the device for an indication that falls outside the labeled FDA-approved use; or (c) a BCBS reviewer applying incorrect information. All three scenarios are addressable.

## Why This Is Appealable

If the device has FDA PMA approval for the patient's indication, the denial is factually wrong and should be overturned on that basis alone — with the PMA documentation as your primary evidence. If the use is technically off-label (the patient's diagnosis is not the precise labeled indication), the appeal shifts to demonstrating compendia support or clinical evidence, similar to an off-label drug appeal. Either way, "not FDA-approved" is not an endpoint — it is a specific factual claim that can be directly rebutted.

## Federal Appeal Framework

• Internal appeal: File within 180 days. Include FDA approval documentation in your initial submission so the internal reviewer can correct the determination without external review being needed.
• External review (ACA §2719): If internal appeal fails, file within 4 months of the final denial. IRO reviewers are clinicians who can independently assess FDA approval status.
• ERISA §503 (self-funded plans): Full-and-fair review applies; a factually incorrect denial is a strong basis for federal court challenge if internal and external review fail.
• Expedited review: Available if delay poses serious health risk.

## Documentation to Gather

1. FDA PMA approval letter or database entry — the FDA's own PMA database (accessible at fda.gov) lists approved devices. Print or reference the specific PMA number for the device at issue. 2. Device labeling — the FDA-approved indications for use, showing the patient's diagnosis falls within (or near) the approved indication. 3. Claim coding review — ask your provider to confirm that diagnosis and procedure codes submitted accurately reflect the device and indication; a coding error can trigger an erroneous "not FDA-approved" denial. 4. Prescriber letter — confirming the device used, its FDA approval status, and the clinical rationale for use. 5. BCBS denial letter — the specific language used, to identify whether BCBS is disputing device approval or indication approval.

## Criteria-Mapping Structure

| Denial Basis (from BCBS letter) | Your Rebuttal Documentation | |---|---| | Device claimed to lack FDA approval | [FDA PMA database entry] | | Indication claimed to be outside approval | [Device labeling, indication match] | | Coding mismatch (if applicable) | [Corrected claim with provider] | | Clinical necessity for approved indication | [Prescriber letter, diagnosis records] |